Zymeworks Stock Price, News & Analysis

Zymeworks (NASDAQ: ZYME) announced multiple presentations at upcoming medical conferences showcasing its oncology portfolio. The presentations will take place at the ASCO Annual Meeting (May 31-June 4, 2025) and ESMO Gynaecological Cancers Congress (June 19-21, 2025).

Key highlights include long-term outcomes and survival data for Ziihera® (zanidatamab-hrii) in HER2-positive gastroesophageal cancer, demonstrating the potential of their Azymetric™ platform. Partner presentations from Jazz Pharmaceuticals, Johnson & Johnson, and Daiichi Sankyo will further validate their expertise in multispecific and bispecific antibodies.

The company will also present Trial-in-Progress posters for two clinical candidates: ZW171 (mesothelin x CD3 targeting bispecific T-cell engager) at ASCO and ZW191 (Folate Receptor α-targeting Antibody-Drug Conjugate) at ESMO-Gyn, with enrollment for both trials progressing as planned.

Zymeworks Inc. (NASDAQ: ZYME), a clinical-stage biotech company focused on developing novel biotherapeutics for cancer, inflammation, and autoimmune diseases, has announced its participation in three major upcoming investor conferences in June 2025:

• Jefferies Global Healthcare Conference on June 4 in New York - Management will conduct one-on-one meetings and a fireside chat at 2:35 pm ET
• Goldman Sachs Global Healthcare Conference on June 11 in Miami - Including one-on-one meetings and a fireside chat at 2:00 pm ET
• Citi European Healthcare Conference on June 17 in London - Management will participate in one-on-one meetings

Zymeworks (NASDAQ: ZYME) presented six posters featuring new preclinical data at the 2025 AACR Annual Meeting, showcasing progress in their antibody-drug conjugate and T cell engager platforms. Key highlights include:

- ZW209: A novel T cell engager demonstrating durable activity in small cell lung cancer, with IND submission expected in 1H-2026

- ZW171: A mesothelin-targeting T cell engager in Phase 1 clinical study showing strong anti-tumor activity in lung, ovarian, and pancreatic cancers

- ZW327: A first-in-class Ly6E-targeting antibody-drug conjugate displaying robust anti-tumor activity across various cancer types

The company also presented findings on their biparatopic antibody-drug conjugates targeting PTK7 and developments in 3D tumor models for improved ADC screening.

Zymeworks Inc. (Nasdaq: ZYME) has appointed Dr. Sabeen Mekan as Senior Vice President of Clinical Development to lead the clinical development strategy for its oncology portfolio and global regulatory affairs. Dr. Mekan brings 18 years of experience in hematology and oncology across academic research, clinical practice, and biopharmaceutical industry development.

The company also announced organizational changes with Dr. Jeff Smith continuing as Executive Vice President & Chief Medical Officer, focusing on autoimmune and inflammatory disease R&D portfolio, while Barbara Schaeffler has been promoted to Senior Vice President of Clinical Development Operations.

Dr. Mekan's previous roles include Executive Director at Gilead Sciences, Senior Medical Director at Daiichi Sankyo, and Medical Director at Bristol-Myers Squibb. She will support Zymeworks' development of next-generation antibody-drug conjugates and multispecific antibody therapeutics for gynecological, thoracic, and digestive system cancers.

Zymeworks (Nasdaq: ZYME), a clinical-stage biotechnology company focused on developing novel biotherapeutics for cancer, inflammation, and autoimmune diseases, has scheduled its first quarter 2025 financial results announcement. The company will release its Q1 2025 results after market close on May 8, 2025, followed by a conference call and webcast at 4:30 pm Eastern Time on the same day. Management will provide both financial updates and a corporate overview during the call.

Zymeworks (Nasdaq: ZYME), a clinical-stage biotechnology company focused on developing multifunctional biotherapeutics for cancer, inflammation, and autoimmune diseases, has announced its participation in two major upcoming investor conferences.

The company will be present at the Needham 24th Annual Virtual Healthcare Conference, where management will conduct one-on-one meetings and deliver a presentation on April 8 at 9:30 am ET. Additionally, Zymeworks will participate in the Stifel 2025 Virtual Targeted Oncology Forum on April 9 at 12:30 pm ET, featuring one-on-one meetings and a fireside chat.

Zymeworks (NASDAQ: ZYME) announced the acceptance of six abstracts for poster presentation at the upcoming AACR Annual Meeting in April 2025. The presentations highlight two key developments:

1. ZW209: A novel trispecific T cell engager targeting DLL3-expressing tumors, showing potent preclinical efficacy and favorable safety profile. The company plans IND submission in 1H-2026.

2. ZW327: A new antibody-drug conjugate (ADC) candidate targeting Ly6E, demonstrating anti-tumor activity and favorable pharmacokinetics in various cancers.

Additional presentations include data on ZW171, a mesothelin-targeting T cell engager in Phase 1 trials, showing promising activity in multiple cancer models, and research on biparatopic antibody-drug conjugates targeting PTK7 in various tumor types.